In both in vitro and in vivo evaluations, our CPT‐bearing chemogene exhibit the targeted co‐delivery of chemo and gene agents to tumor site, efficient BCL‐2 gene knockdown, and strong induced apoptosis of cancer cells, together leading into an enhanced antitumor efficacy. This evidence concerns the gene BCL2 and cancer.